Daratumumab

• A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting
  2023-505221-14-00 Phase II 5 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants wit… Recruiting
  2024-517382-17-00 Phase II 1 country Universitaetsklinikum Heidelberg AöR
• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex… Recruiting
  2024-514139-50-00 Phase III 12 countries Pfizer Inc.
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting
  2023-503442-30-00 Phase III 14 countries Janssen - Cilag International
• An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients wit… Recruiting
  2024-511635-94-00 Phase II 1 country Fondazione Italiana Linfomi Ets
• An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of … Recruiting
  2024-518263-35-00 Phase II 1 country Hellenic Society Of Hematology
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 Phase II 10 countries Bristol-Myers Squibb Services Unlimited Company
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m… Ended
  2024-517020-18-00 Phase II 1 country Fundacion PETHEMA
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Ended
  2024-511188-26-00 Phase III 9 countries Kite Pharma Inc.
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended
  2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• RElapse from Mrd Negativity As iNdication for Treatment Ended
  2023-510215-18-00 Phase II/III 2 countries Oslo University Hospital HF
• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone… Ended
  2023-508310-41-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of f… Ended
  2023-508212-38-00 Phase II 3 countries North Estonia Medical Centre Foundation
• A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma - I… Ended
  2024-514101-65-00 Phase II 1 country Centre Hospitalier Universitaire De Lille
• Phase II, Multicenter Study to Assess Safety and Efficacy of Combination of Sargramostim with D-VCd Therapy (Daratumumab, Cyclophosphamide, … Ended
  2024-518658-18-00 Phase II 1 country Medical University Of Warsaw
• An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab… Ended
  2024-514016-26-00 Phase II 1 country Fundacion Pethema
• A Clinical Study to evaluate the long-term safety of Daratumumab in combination with standard bone marrow cancer treatment regiments Ended
  2022-500138-27-01 Phase III 9 countries Janssen - Cilag International
• A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMB… Ended
  2024-516147-32-00 Phase I/II 1 country Hellenic Society Of Hematology
• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin… Ended
  2023-503467-41-00 Phase III 9 countries Janssen - Cilag International
• Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment… Ended
  2024-518870-15-00 Phase II 1 country Fundacion PETHEMA
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended
  2024-510800-35-00 Phase III 16 countries Celgene Corp.
• Daratumumab in ME/CFS Ended
  2024-512500-19-00 Phase II 1 country Helse Bergen HF
• Belantamab Mafodotin in combination with Daratumumab, Lenalidomide and Dexamethasone for the treatment of patients with newly diagnosed mul… Ended
  2024-515634-32-00 Phase I/II 1 country Hellenic Society Of Hematology
• PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION (… Ended
  2024-515037-15-00 Phase II 1 country Assistance Publique Hopitaux De Paris

Showing 25–48 of 78 trials